MRSN
Mersana Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
High Gross Profit Margin
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MRSN
Mersana Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing antibody drug conjugates to cure various cancers
840 Memorial Drive, Cambridge, MA 02139
--
Mersana Therapeutics, Inc., was incorporated in Delaware in February 2002 under the name Nanopharma Corp. In November 2005, they changed their name to Mersana Therapeutics, Inc. The Company is a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates, or ADCs, that provide clinically meaningful benefits to cancer patients with significant unmet needs. The company leverages 20 years of industry learning in the ADC field to develop proprietary technologies that enable designed ADCs to have better efficacy, safety and tolerability relative to existing ADC therapies. In addition, the Company entered into a strategic partnership with Takeda Pharmaceutical Company Limited or Takeda, whereby the Company acquired the rights to the XMT-1522 outside the United States and Canada. The company also has strategic R&D partnerships with Takeda and Merck KGaA for the development and commercialization of additional ADC product candidates for a limited number of targets selected by partners based on their Dolaflexin platform.
Earnings Call
Q2/2025
Estimate EPS-0.17
Actual EPS-4.87
Estimate Revenue6.06M
Actual Revenue3.06M
Mersana Therapeutics Q2 2025: Unpacking Key Contradictions in Clinical Strategies and Patient Eligibility
Aug 13,2025 11:50
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MRSN has released its 2025 Q3 earnings. EPS was reported at -1.51, versus the expected -0.89, missing expectations. The chart below visualizes how MRSN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MRSN has released its 2025 Q3 earnings report, with revenue of 11.01M, reflecting a YoY change of -12.61%, and net profit of -7.54M, showing a YoY change of 34.40%. The Sankey diagram below clearly presents MRSN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
